wire - news in brief

« BACK

Business/Economics



Results 1 - 50 of 322.
1 2 3 4 5 7 Next »

Medicine/Pharmacology - Business/Economics
20.12.2016
Novartis bolsters ophthalmology pipeline through acquisition of Encore Vision, Inc
Novartis confirms its leadership in ophthalmology by entering a new therapy area. Acquisition of Encore Vision, Inc.
Business/Economics
16.12.2016
Switzerland ratifies Croatia protocol
Bern, 16.12.2016 - Switzerland has ratified the protocol extending the free movement of persons to Croatia.
Medicine/Pharmacology - Business/Economics
16.12.2016
Novartis bolsters innovative dermatology portfolio through acquisition of Ziarco Group Limited
Acquisition to add a once-daily oral H 4 receptor antagonist, ZPL389, to treat atopic dermatitis, commonly known as eczema, to the Novartis industry-leading pipeline    Investigational ZPL389 showed a clinically and statistically significant improvement of eczema lesions, leading to a 50% reduction in EASI score compared to placebo after eight weeks of treatment with a favorable safety profile   Eczema is a chronic, inflammatory skin condition a
Business/Economics - Careers/Employment
09.12.2016
Business/Economics - Astronomy
01.12.2016
President Schneider-Ammann attends ESA Ministerial Council
Bern, 01.12.2016 - On 1 December, President Johann N. Schneider-Ammann addressed the ministers of the 22 member states of the European Space Agency ESA and Canada in Lucerne.
Business/Economics - Computer Science/Telecom
01.12.2016
Swiss businesses are good process innovators
Swiss businesses are good process innovators
Switzerland's economy is facing some tough challenges: technologies are developing rapidly, processes are being amalgamated both inside and outside production facilities, and business units are becoming increasingly interconnected.
Medicine/Pharmacology - Business/Economics
29.11.2016
Novartis Access shares one-year learnings and announces memorandum of understanding with Rwanda
Rwanda becomes third country to launch Novartis Access portfolio against chronic diseases with first deliveries planned in early 2017 Since September 2015, Novartis Access has delivered more than 100
Medicine/Pharmacology - Business/Economics
21.11.2016
Novartis acquires Selexys Pharmaceuticals Corporation and SelG1 antibody for reduction of pain crises in sickle cell disease (SCD)
Deal followed results of Phase II SUSTAIN study of SelG1 in reduction of vaso-occlusive pain crises, a major complication of SCD with limited treatment options   Results of SUSTAIN will be presented
Business/Economics
18.11.2016
Transitioning the publication system towards Open Access: Study proposes pragmatic scenario
Transitioning the publication system towards Open Access: Study proposes pragmatic scenario
For the first time, a study has developed scenarios for restructuring transitioning Switzerland's scientific publication system towards Open Access (OA). The study was initiated by the SNSF in collaboration with the Scientific Information programme (SUC P-2) run by swissuniversities. It recommends a model that proposes a pragmatic and flexible way of making publicly funded research freely available at no charge and with no delay.
Business/Economics
04.11.2016
Switzerland intensifies relations with Mexico
Bern, 04.11.2016 - President Johann N. Schneider-Ammann has paid a two-day presidential visit to Mexico.
Careers/Employment - Business/Economics
26.10.2016
A 10 million euro round of financing for the start up Coorpacademy
A 10 million euro round of financing for the start up Coorpacademy
Coorpacademy, a startup based in EPFL's Innovation Park, has completed a 10 million euro round of financing.
Business/Economics - Medicine/Pharmacology
25.10.2016
Novartis delivered solid third quarter with Growth Products[1] offsetting Gleevec patent expiration; several positive readouts for potential blockbusters
Novartis delivered solid third quarter with Growth Products[1] offsetting Gleevec patent expiration; several positive readouts for potential blockbusters
Novartis delivered solid third quarter with Growth Products offsetting Gleevec patent expiration; several positive readouts for potential blockbusters Q3 net sales (-1% cc and USD) broadly in line wit
Business/Economics
21.10.2016
Business/Economics - Architecture
06.10.2016
Business/Economics - Politics
30.09.2016
Seven new professorships at the Department of Economics
The University of Zurich has proven that it can meet several US elite universities at eye level when it comes to recruiting the best talents.
Medicine/Pharmacology - Business/Economics
28.09.2016
Sandoz invites young entrepreneurs to enter Sandoz HACk, a global competition to help solve healthcare access challenges
Despite significant advances made by modern medicine, universal access to healthcare is still arguably the single largest unmet medical need   Sandoz "HACk" - Healthcare Access Challenge - is a compe
Business/Economics - Administration/Government
23.09.2016
Medicine/Pharmacology - Business/Economics
22.09.2016
Novel Novartis malaria compound shows potential to be effective against infections resistant to all currently available antimalarial drugs
Results published in the New England Journal of Medicine demonstrate that KAF156 shows activity against blood and liver stages of malaria parasites, including artemisinin-resistant parasites   KAF156, currently in phase IIb, is the first compound from a novel class of antimalarials known as imidazolopiperazines   Antimalarials with new mechanisms of action are urgently needed to tackle emerging parasite resistance to current therapies; Novartis
Medicine/Pharmacology - Business/Economics
19.09.2016
Medicine/Pharmacology - Business/Economics
15.09.2016
Novartis presents new positive data at EHMTIC showing AMG 334 significantly reduces monthly migraine days in chronic migraine
Detailed results from Phase II study in chronic migraine prevention showed patients on AMG 334 (erenumab) were significantly more likely to experience a 50% or more reduction in monthly migraine days compared to placebo   Chronic migraine is the most disabling form of the disease, and is associated with substantial personal pain and disability, and financial cost to society ,   AMG 334 is being co-developed by Novartis and Amgen for the preventi
Business/Economics - Administration/Government
14.09.2016
New funding programme to serve as launch pad for Swiss start-ups
Bern, 14.09.2016 - This autumn, the European Space Agency (ESA) and the State Secretariat for Education, Research and Education (SERI) will open an ESA Business Incubation Centre (ESA BIC) in Switzerland.
Business/Economics
07.09.2016
Industry meets science
Industry meets science
A record number of visitors attended this year's Industry Day. Around 550 representatives from industry and business met with scientists for a lively debate on the Hönggerberg.
Agronomy/Food Science - Business/Economics
01.09.2016
Nadja El Benni to head ‘Competitiveness and System Evaluation’ Research Division
Bern, 01.09.2016 - Dr. Nadja El Benni was appointed Head of the ‘Competitiveness and System Evaluation' Strategic Research Division by Agroscope Council on 25 August 2016.
Business/Economics - Mechanical Engineering/Mechanics
18.08.2016
Super stair-climbers
Super stair-climbers
They have big ambitions: nine students from ETH Zurich and ZHdK are preparing to take on developers from renowned manufacturers and universities from around the world with their "Scewo" wheelchair at the Cybathlon.
Computer Science/Telecom - Business/Economics
16.08.2016
Innovative IT solution to tackle cyber crime
Innovative IT solution to tackle cyber crime
An ETH spin-off, xorlab, has ambitious plans: it has developed a unique IT security solution that provides more effective protection against hacker attacks.
Administration/Government - Business/Economics
28.07.2016
More than two million dollars to rethink cybersecurity
!- 28.07.16 - Cyberhaven is developing a new concept for information security. The EPFL spin-off is opening its second office in Boston and has raised more than 2 million dollars in venture capital.
Business/Economics - Medicine/Pharmacology
19.07.2016
Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects
Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects Q2 net sales were flat (0% cc ) as Growth Produc
Medicine/Pharmacology - Business/Economics
13.07.2016
Sandoz biosimilar etanercept recommended by FDA advisory committee for approval to treat multiple inflammatory diseases
Committee votes unanimously in favor of the Sandoz proposed biosimilar etanercept for all approved indications of the reference product                                                                
Business/Economics - Medicine/Pharmacology
23.06.2016
Medicine/Pharmacology - Business/Economics
15.06.2016
Novartis expands partnership with Medicines for Malaria Venture to develop next-generation antimalarial treatment
Novartis will lead the development of antimalarial compound KAF156 with scientific and financial support from Medicines for Malaria Venture in collaboration with the Bill & Melinda Gates Foundati
Medicine/Pharmacology - Business/Economics
08.06.2016
Novartis presents new scientific evidence for Cosentyx in ankylosing spondylitis and psoriatic arthritis patients at EULAR 2016
Up to 80% of ankylosing spondylitis and 84% of psoriatic arthritis patients treated with Cosentyx at two years had no radiographic progression in the spine or joints , respectively ,     Cosentyx may
Medicine/Pharmacology - Business/Economics
25.05.2016
Novartis highlights its strong foundation for long-term, sustainable growth at the third Meet Novartis Management event
Outlines actions underway to accelerate launch of Entresto , including further expansion of US primary care field force, and reinforce strong uptake of Cosentyx Highlights leading pipeline of second
Medicine/Pharmacology - Business/Economics
24.05.2016
Sandoz’ biosimilar rituximab regulatory submission accepted by European Medicines Agency
Sandoz advances biosimilar portfolio with sixth major biosimilar file acceptance in less than one year Sandoz is seeking approval for all indications included in the reference product's label Sandoz'
Medicine/Pharmacology - Business/Economics
21.05.2016
Novartis’ Entresto given strong Class I recommendation in both US and EU heart failure guidelines, less than a year after regulatory approvals
Novartis' Entresto given strong Class I recommendation in both US and EU heart failure guidelines, less than a year after regulatory approvals US guidelines now recommend Entresto as standard of care
Medicine/Pharmacology - Business/Economics
20.05.2016
Business/Economics
20.05.2016
NEST: building of the future is up and
A unique research and innovation platform has opened its doors: on 23 May 2016, the modular experimental building NEST was inaugurated on the Dübendorf campus of the two research institutes Empa and Eawag.
Medicine/Pharmacology - Business/Economics
19.05.2016
Novartis announces investment in FortiHFy clinical program of Entresto and heart failure
Forti fying H eart F ailure clinical evidence and patient qualit y of life (FortiHFy) is an umbrella clinical program comprising over 40 active or planned trials   The global clinical program will generate additional data on symptom reduction, efficacy, safety, quality of life benefits and real world evidence with Entresto   Investigators and patients from over 50 countries to participate over 5 years - Novartis today announced the establishment
Business/Economics
18.05.2016
EPFL and AXA announce the creation of a Research Program
18.05.16 - Bryan Ford, a world-renowned expert in information security, has been named an Associate Professor at EPFL in Lausanne, Switzerland thanks to the support of the AXA Research Fund. The Fund engaged 1.5 million euros to support this 12 year-project.
Business/Economics - Medicine/Pharmacology
21.04.2016
Novartis delivered solid Q1 despite Gleevec loss of exclusivity; investing behind new launches for long-term growth
Net sales up 1% (cc ), as Growth Products offset Gleevec impact Growth Products grew 24% (USD) to USD 3.9 billion, or 34% of Group net sales Cosentyx (USD 176 million) continues to grow strongly,
Physics/Materials Science - Business/Economics
13.04.2016
Opening of Empa’s Coating Competence
At Empa's new Coating Competence Center, which has just opened, tailor-made surface technologies find their way from the research labs to marketable industrial applications.
Business/Economics - Life Sciences
06.04.2016
Five promising EPFL spin-offs will go after the US market
Five promising EPFL spin-offs will go after the US market
06.04.16 - Twenty Swiss start-ups, including five EPFL spin-offs, will head to the east coast of the United States in June for a weeklong immersion in the business world.
Business/Economics - Medicine/Pharmacology
31.03.2016
Novartis publishes updated 2015 segment financials reflecting new division structure
Updated segment financials reflect transfer of Ophthalmic Pharmaceuticals franchise from Alcon to Pharmaceuticals, and 19 mature products from Pharmaceuticals to Sandoz, as outlined in Q4 and FY 2015
Computer Science/Telecom - Business/Economics
15.03.2016
EPFL sets up center for Scala programming language
EPFL sets up center for Scala programming language
15.03.16 - Twelve years after it was designed at EPFL, the Scala programming language is used by more than a half million developers around the world and by companies like Twitter, Netflix and Swisscom.
Administration/Government - Business/Economics
27.02.2016
Reining in the ’chaebol’
South Korea's mighty conglomerates dominate research and development. But at what cost to innovation? By Mark Zastrow (From "Horizons" no.
Business/Economics - Careers/Employment
23.02.2016
Novartis shareholders approve all resolutions proposed by Board of Directors
Shareholders approve 19 th consecutive dividend increase to CHF 2.70 (+4%) per share for 2015   Dr. Joerg Reinhardt confirmed by shareholders as Chairman of the Novartis Board of Directors as
Medicine/Pharmacology - Business/Economics
18.02.2016
Alcon expands leadership position in treating glaucoma through acquisition of Transcend Medical, Inc
Acquisition to add minimally-invasive glaucoma surgery (MIGS) device to pipeline, expanding Alcon's surgical presence in a new category to treat glaucoma   The goal of MIGS is to reduce or eliminate
Business/Economics
12.02.2016
Offshoring looms after the removal of the CHF/¤ exchange-rate floor
12.02.16 - Swiss companies may be preparing to shift production out of the country after the franc was unpegged from the euro. This is one of the main conclusions of the first academic study of the topic, which was conducted by economists from EPFL and the University of Geneva. In January 2015, the Swiss National Bank (SNB) announced that it would abandon the currency floor of 1.2 Swiss francs per euro.
1 2 3 4 5 7 Next »